Cart 0
Acquired Haemophilia Pipeline Analysis 2018

Acquired Haemophilia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • $2,400.00
  • Publishing Date: February 2018
  • Format: PDF
Sample Request

Acquired Haemophilia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Acquired Haemophilia Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Acquired haemophilia is an autoimmune rare bleeding disorder caused when a person’s own body produces antibodies which attack the blood clotting factors mostly factor VIII. In normal condition, clotting factors are proteins which help the blood to clot normally. As a consequence, a person suffering from acquired haemophilia develop complications related to abnormal and uncontrolled bleeding in the muscles, soft tissues and skin, during surgery or in case of trauma. Symptoms include nose bleeding known as epistaxis, blood in urine known as haematuria and urogenital or gastrointestinal bleeding. Other symptoms include bruising all over the body and haematomas which cause solid swellings due to congealed blood.

The report provides acquired haemophilia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Pfizer Inc., Bayer AG, Shire, CSL and Genentech, Inc. among others.


  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development Introduction Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code Strategic Developments Clinical trials Clinical trial results Patents Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Shire
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Novo Nordisk A/S
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Genentech, Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. CSL
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. rEVO Biologics, Inc
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. OPKO Health Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Pfizer Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Bayer AG
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Bioverativ
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. HEMA Biologics, LLC
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Catalyst Biosciences
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT

Related Reports
Back to the top